Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common cholesterol pill flush out 'forever chemicals' from veterans' bodies?

NCT ID NCT07592858

Disease control Sponsor: University of Rhode Island Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called colesevelam, normally used for high cholesterol, can help lower levels of PFAS (often called 'forever chemicals') in the blood of veterans. About 50 veterans with high PFAS levels will receive either the drug or a placebo for a period, and researchers will measure changes in their blood and cholesterol. The goal is to find a safe way to reduce these chemicals and improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Male or female Veterans aged 25- 65 who have serum PFAS \>20 ng/ml exceeding National Academy of Science guidance. * Written informed consent will be obtained. * Outpatient. * Agreeable to participate in sharable data and biorepository. Exclusion: * Under the age of 25 years * Unable or unwilling to sign the informed consent statement and HIPAA Authorization form * Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period. * Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction * Be receiving any investigational drug other than Colesevelam or participating in any other investigational study. * Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator. * Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results. * Those with significant cardiovascular disease including treatment with inotropes. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burn pit exposure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia PFAPA syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burn pit exposure Environmental exposures Forever chemicals Hyperlipidemia (E.G., hypercholesterolemia) Hyperlipidemias, hypercholesterolemia, mixed dyslipidemia Military exposure Occupational exposure to chemicals PFAS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Robley Rex VA Medical Center

    Louisville, Kentucky, 40245, United States

  • VA Maine Healthcare System

    Augusta, Maine, 04330, United States

  • VA Maine Healthcare System

    Augusta, Maine, 04330, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.